About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Colorectal Cancer Clinical Trials in New York | 381 Studies | Clareo Health

Clinical Trials Colorectal CancerNew York

Colorectal Cancer Clinical Trials in New York

Find 381 clinical trials for colorectal cancer near New York, New York. Connect with research centers in your area.

All Colorectal Cancer trials nationwide All trials in New York

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1-20 of 381 trials

TERMINATEDPhase 1< 1 mile

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

Day One Biopharmaceuticals, Inc.57 participantsStarted Jan 2023

Los Angeles, California, United States • Los Angeles, California, United States • Stanford, California, United States +11 more locations

Active Not RecruitingPhase 2< 1 mile

Acupuncture Pilot Study for Cancer-related Cognitive Function

NCT04007770

This study is being done to explore whether acupuncture can improve cognitive difficulties in patients diagnosed with cancer.

Stage I Breast CancerStage II Breast CancerStage III Breast Cancer+10 more

Memorial Sloan Kettering Cancer Center48 participantsStarted Jul 2019

Basking Ridge, New Jersey, United States • Middletown, New Jersey, United States • Montvale, New Jersey, United States +3 more locations

Colorectal Cancer Trials in Other Cities

Los Angeles Chicago Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 2< 1 mile

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

This phase II trial studies the side effects of chemotherapy and intensity modulated radiation therapy in treating patients with low-risk HIV-associated anal cancer, and nivolumab after standard of care chemotherapy and radiation therapy in treating patients with high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab after standard of care chemotherapy and radiation therapy may help reduce the risk of the tumor coming back.

AIDS-Related Anal CarcinomaAnal Margin Squamous Cell CarcinomaAnal Non-Keratinizing Squamous Cell Carcinoma+7 more

National Cancer Institute (NCI)40 participantsStarted Aug 2022

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Tampa, Florida, United States +11 more locations

Active Not RecruitingPhase 3< 1 mile

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

NCT02997228

This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Metastatic Colorectal AdenocarcinomaStage IV Colorectal Cancer AJCC v7

National Cancer Institute (NCI)120 participantsStarted Jan 2018

Kingman, Arizona, United States • Jonesboro, Arkansas, United States • Anaheim, California, United States +442 more locations

RECRUITINGPhase 3< 1 mile

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

NCT03803553

This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab

Metastatic Colon CancerStage III Colon Cancer

Massachusetts General Hospital400 participantsStarted Apr 2020

Boston, Massachusetts, United States • New York, New York, United States • New York, New York, United States

Active Not RecruitingPhase 3< 1 mile

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Advanced Colorectal CancerMetastatic Colorectal Cancer

Mirati Therapeutics Inc.461 participantsStarted Jul 2021

Alabaster, Alabama, United States • Bessemer, Alabama, United States • Birmingham, Alabama, United States +416 more locations

RECRUITINGPhase 1/2< 1 mile

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

CancerColorectal CancerSolid Tumor+12 more

Parabilis Medicines, Inc.595 participantsStarted May 2023

Scottsdale, Arizona, United States • Tucson, Arizona, United States • Los Angeles, California, United States +22 more locations

Active Not RecruitingPhase 1< 1 mile

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185

The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.

Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerColorectal Cancer+2 more

Eli Lilly and Company750 participantsStarted Oct 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Duarte, California, United States +53 more locations

Active Not Recruiting< 1 mile

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

NCT03038568

The purpose of the study is to see how measurements of tumor differences vary with slight changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even in the setting of variable scan parameters and variable contrast timing. Participants will be consented to undergo an additional CT of their abdomen.

Colorectal Cancer Metastatic

Memorial Sloan Kettering Cancer Center169 participantsStarted Jan 2017

New York, New York, United States • Houston, Texas, United States

Active Not RecruitingPhase 1/2< 1 mile

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more

Eli Lilly and Company857 participantsStarted May 2017

Scottsdale, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +82 more locations

Not Yet RecruitingNA< 1 mile

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

NCT07225309

The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.

Breast CancerProstate CancerColorectal Cancer+9 more

Memorial Sloan Kettering Cancer Center300 participantsStarted Jun 2026

New York, New York, United States • Mexico City, Mexico

RECRUITINGPhase 1< 1 mile

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

Iambic Therapeutics, Inc383 participantsStarted Mar 2024

La Jolla, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +45 more locations

Active Not Recruiting12 miles

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

NCT03516942

This research trial studies the financial burden in patients with stage I-III colon or rectal cancer who are undergoing treatment. Collecting data from patients about their cost and quality of life may help doctors to better understand the impact of cancer treatment on a patient?s employment and finances.

Stage I Colon Cancer AJCC v8Stage I Rectal Cancer AJCC v8Stage II Colon Cancer AJCC v8+15 more

ECOG-ACRIN Cancer Research Group565 participantsStarted Jun 2018

Anchorage, Alaska, United States • Anchorage, Alaska, United States • Anchorage, Alaska, United States +713 more locations

RECRUITINGPhase 221 miles

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.

Ras-mutated Metastatic Colorectal CancermCRCMSS Metastatic Colorectal Cancer

Oncolytics Biotech60 participantsStarted Apr 2026

Homewood, Alabama, United States • Florham Park, New Jersey, United States • Canton, Ohio, United States

RECRUITINGPhase 270 miles

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT06820463

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Metastatic Colorectal Cancer

AbbVie390 participantsStarted Apr 2025

Duarte, California, United States • New Haven, Connecticut, United States • Hinsdale, Illinois, United States +41 more locations

RECRUITINGPhase 1155 miles

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

NCT05464030

The purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2) Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program

Colorectal Cancer

EMD Serono Research & Development Institute, Inc.200 participantsStarted Aug 2022

Encinitas, California, United States • Fresno, California, United States • Providence, Rhode Island, United States +32 more locations

Active Not RecruitingPhase 1190 miles

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

NCT02298959

This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ziv-afibercept works by decreasing blood and nutrient supply to the tumor, which may result in shrinking the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ziv-aflibercept together with pembrolizumab may be a better treatment for patients with advanced solid tumors.

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Colorectal CarcinomaMetastatic Malignant Solid Neoplasm+12 more

National Cancer Institute (NCI)59 participantsStarted Apr 2015

Tampa, Florida, United States • Tampa, Florida, United States • Tampa, Florida, United States +6 more locations

RECRUITINGPhase 1190 miles

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

NCT07300150

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Colorectal CancerPancreatic CancerNon-Small Cell Lung Cancer+1 more

PAQ Therapeutics, Inc.195 participantsStarted Nov 2025

Boston, Massachusetts, United States • San Antonio, Texas, United States • San Antonio, Texas, United States +2 more locations

RECRUITINGPhase 3483 miles

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

NCT07549412

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.

Metastatic Colorectal Cancer

EMD Serono Research & Development Institute, Inc.1,020 participantsStarted May 2026

Peoria, Illinois, United States • Sterling Heights, Michigan, United States • Columbia, Missouri, United States +5 more locations

RECRUITING2428 miles

Early Detection of Advanced Adenomas and Colorectal Cancer

NCT06342440

This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.

Colorectal CancerColorectal NeoplasmsColorectal Polyp+15 more

City of Hope Medical Center2,000 participantsStarted Mar 2020

Monrovia, California, United States • San Diego, California, United States • Dalian, China +3 more locations

Page 1 of 20Next

Other Conditions in New York

Breast Cancer Lung Cancer Prostate Cancer Melanoma Leukemia Lymphoma